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ABSTRACT:
Using non-steroidal anti-inflammatory drugs as over-the-counter pain-killers may predispose to gastric ulcer as a side effect.
The objective of this study is to investigate the possible benefit of a common statin used in hyperlipedemic patients;
atorvastatin (AtoR), in ameliorating the ulcerogenic effect of indomethacin (IndoM), and to explore the possible mechanisms
involved. AtoR (10 mg/kg/day) was administered orally for 7 days. At day 7, gastric ulcer was induced by a single dose of
IndoM (40 mg/kg i.p.), with or without AtoR pre-treatment. IndoM induced gastric ulcer as evident by notable gastric
ulceration in histopathological sections compared to normal control. Gastric tissue in rats receiving IndoM showed
significantly higher oxidative stress markers as lipid peroxidation represented by increased malondialdehyde (MDA)
content, with significant decrease in gastric tissue nitric oxide (NO) and prostaglandin E2 (PGE2) levels, as well as reduction
in catalase and superoxide dismutase antioxidant enzymatic activities. In addition, IndoM induced inflammatory signs as
shown by the significant increase in tumor necrosis factor-alpha (TNF-α) level assessed via ELISA. Pre-administration of
AtoR significantly decreased ulcer index (16±1) compared to that of IndoM alone (34±2). In addition, AtoR restored normal
gastric histological structure and reverted oxidative and inflammatory markers tested. AtoR confers gastro-protection against
IndoM-induced ulceration via reducing gastric oxidative stress and increasing gastric NO and PGE2 levels, as well as
decreasing the inflammatory marker; TNF-α.
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INTRODUCTION:
Gastric mucosa is considered as one of the first line barriers protecting the body from the hazards of ingested exogenous
xenobiotics and microbes. One of the main factors that cause erosion of the epithelium lining the stomach, and eventually
gastric ulceration, is the administration of non-steroidal anti-inflammatory drugs (NSAIDs) widely used as over-the-counter
pain-killers1. Nearly quarter of the chronic users of NSAIDS develop gastric ulceration 2, with higher incidence of gastric
ulceration in patients using NSAIDs that non-selectively inhibit cyclooxygenase enzymes, as indomethacin (IndoM). One of
the mechanisms through which IndoM can induce gastric ulceration is via oxidative stress caused by increased production of
reactive oxygen species and lipid peroxidation products3. Other mechanisms for IndoM-induce gastric injury include
suppressing the formation of prostaglandins, which trigger different gastric mucosal defense mechanisms, including
stimulating mucus and bicarbonate secretion, elevating mucosal blood flow, increasing epithelial cell resistance to cytotoxic
injury and suppress recruitment of leucocytes into mucosa(1). Prostaglandins can also inhibit the release of inflammatory
mediators, as tumor necrosis factor (TNF)-α which promotes gastric epithelial cell apoptosis4.
Atorvastatin (AtoR) is a well-tolerated cholesterol-lowering statin, whose mechanism of action involves inhibiting 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thus reducing cholesterol production via the mevalonate
pathway5. We have previously shown that AtoR possess antioxidant and anti-inflammatory effects against doxorubicin-
induced hepato-renal damage6. In the present study, we aim at investigating the possible gastro-protective effects of AtoR
against IndoM-induced gastric ulceration, and to explore the possible mechanisms involved.
MATERIALS AND METHODS
Chemicals
Atorvastatin was kindly provided by Eipico (Egypt). Indomethacin was purchased from Nile Co. (Egypt). Kits for the
estimation of catalase (CAT) and superoxide dismutase (SOD) enzymatic activities were purchased from Biodiagnostic
(Egypt). Prostaglandin E2 (PGE2) ELISA- kit was obtained from Cayman (USA) while TNF-α ELISA kit was purchased
from WKEA-Med supplies Corp. (China). All other chemicals were of analytical grade and were obtained from commercial
source.
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Experimental procedures
Twenty four male Albino rats (180–200 g) were purchased from the National Research Centre, Giza, Egypt. Throughout the
experiments, rats were housed in the standard animal facility (3 or 4 animals/cage) under normal laboratory conditions, with
free access to standard rodent chow and water. All experimental procedures were conducted in accordance with the
Institutional Animal Ethics Committee guidelines for animal care and use, Faculty of Medicine, Minia University, Egypt.
Animals were left to acclimatize for one week, after which they were divided into 3 groups (n=8 each). The first group
served as the control group. In the second group, gastric ulcer was induced using a single intra-peritoneal (I.P.) dose of
IndoM of 40 mg/kg7. The third group also received IndoM at the same described dose, but with prior administration of oral
AtoR as a single daily dose of 10 mg/kg/day for 7 days by oral route (gastric gavage)6.
Macroscopic and microscopic examinations
The animals were sacrificed 3 hrs after IndoM treatment. Stomach tissues were excised, washed with ice-cold saline, opened
along the greater curvature, re-washed by cold saline to remove gastric contents and blood clots. The macroscopical mucosal
lesions was evaluated using gastric ulcer index (UI), where gastric mucosal lesions were counted, using a ×5 magnifier lens
to assess the formation of ulcers, and the mean lesion score for each group was calculated8. The gastric tissue was then
divided into two parts. One part was kept frozen for biochemical evaluation of gastric injury assays in the scraped mucosa.
The other portion was fixed in 10% buffered neutral formalin solution, dehydrated in gradual ethanol (70-100%), cleared in
xylene, and embedded in paraffin. Five-m thick paraffin sections were prepared and then stained with hematoxylin and
eosin (H&E) dyes for histological examinations.
Analysis of gastric mucosa biochemical parameters
Gastric scraped mucosal tissue content of lipid peroxides was determined by biochemical assessment of thiobarbituric acid
reacting substance through spectrophotometric measurement of color at 535 nm (Beckman DU-64 UV/VIS
spectrophotometer), using 1,1,3,3-tetramethoxypropane as standard9. The results were expressed as equivalents of
malondialdehyde (MDA) in tissue homogenate in nmol/g tissue. Mucosal content of NO was also spectrophotometrically
determined in tissue homogenate as described(10) using copper–cadmium alloy as a reducing agent that reduces nitrate into
stable nitrite (Gries reaction). The results were expressed as nmol/g tissue. Assessment of catalase antioxidant enzymatic
activity was determined in tissue homogenate from the rate of decomposition of H2O2 at 510 nm by colorimetric kit. The
results were expressed as unit/g tissue. Gastric mucosal SOD enzymatic activities were quantified according to the
manufacturers’ guidelines. The assay depended on the ability of SOD enzyme to inhibit the phenazine methosulphate-
mediated reduction of nitroblue tetrazolium dye. The change in absorbance at 560 nm was measured over 5 min. SOD
activity results were expressed in U/0.1 g tissue.
Evaluation of PGE2 and TNF-α level in gastric mucosal tissue
Production of PGE2 in gastric tissue homogenate supernatant was determined using ELISA kit according to the
manufacturer's instructions. Briefly, PGE2 was converted into its stable derivative (Bicyclo PGE2) which was measurable by
the kit. The tissue supernatant and standards were added to a 96-well plate, pre-coated with goat polyclonal anti-mouse IgG.
After incubation period with PGE2 acetylcholinesterase conjugated with the PGE2 Tracer, Ellman’s reagent was applied for
60 min, yielding a distinct yellow color, which was measured using ELISA plate reader at 412 nm. Results were calculated
using the standard curve which was expressed as pg/mg tissue. TNF-α was also evaluated using a commercial ELISA kit
according to manufacturer's instructions. Briefly, 10 µl of tissue homogenate was dispensed in 40 µl of sample diluent
solution, mixed and incubated for 30 min at 37C. The plate was washed for five times with 30-fold diluted wash buffer and
dried. To each well, 50 µl enzyme conjugate was added, incubated then washed as previously described. After drying the
plate, 50 µl of each of substrate A and B were added to each well and the plate was incubated for 15 min at 37C. The
reaction was stopped by adding 50 µl stop solution. The plate was then read using ELISA plate reader at 450 nm.
Statistical analysis
The data was analyzed by one way ANOVA followed by Dunnett Multiple Comparison Test. The values are represented as
means ± S.E.M. All statistical analysis was done using GraphPad Prism (GraphPad Prism software, 2011). The differences
were considered significant when the calculated P value is less than 0.05.
RESULTS:
Effect of atorvastatin on histological picture and gastric ulcer index in indomethacin-treated rats
Control group showed no gastric ulceration, with normal gastric epithelial lining and lacked any vascular congestion or
erythrocytic extravasation (Figure 1A). On the other hand, animal group receiving IndoM showed alteration in microscopic
histological gastric architecture, with irregular thin gastric mucosa, vascular congestion, inflammatory cellular infiltration
and erythrocyte extravasation (Figure 1B). Microscopic examination of gastric ulcers in this group showed disruption in
gastric mucosal membrane continuity, with profound ulceration in gastric epithelium extending deep into the glandular layer.
Pre-treatment with AtoR succeeded in restoring normal gastric histological structure (Figure 1C). The macroscopic picture
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reflected similar results, where IndoM caused induction of gastric ulceration as shown by the significant increased in UI
(34±2) compared to control (Figure 1D). Pre-administration of AtoR significantly decreased ulcer index (16±1) compared to
animals receiving IndoM alone (P < 0.05).
Effect of atorvastatin on gastric oxidative stress markers in indomethacin-treated rats
In rats receiving IndoM alone, oxidative stress was evident in gastric mucosal tissue, as indicated by the significant increase
of the lipid peroxidation product content (MDA), with significant decrease in gastric tissue NO levels, as well as diminished
antioxidant enzymatic activities of catalase and SOD compared to control (Table 1). Pre-treatment with AtoR significantly
reversed all oxidative stress markers tested compared to the group receiving IndoM alone (P < 0.05).
Figure 1: Effect of atorvastatin (AtoR) on histopathology of gastric tissues in indomethacin (IndoM)-induced gastric
ulcer in rats
Microscopic picture of the stomach stained with hematoxylin and eosin (×100) showing: A- control group with normal
gastric mucosa. B- IndoM-treated group with profound ulceration disrupting gastric surface epithelium and extending deep
into the glandular layer (star). Areas without ulceration (insert) show irregular thin gastric mucosa, vascular congestion,
inflammatory cellular infiltration (arrow) and erythrocyte extravasation (arrowhead). C- Combined IndoM/AtoR-treated
group showing regular gastric mucosa, with mild erythrocyte extravasation (arrowhead). D- Graph showing ulcer index. The
results are mean ± SEM for 8 animals/group. a Significant difference compared to control.b Significant difference compared
from IndoM-treated group. Significant difference is reported when P < 0.05.
Table 1: Effect of atorvastatin (AtoR) on gastric catalase, superoxide dismutase (SOD) malondialdehyde (MDA) and
nitric oxide (nitrite/nitrate) levels in rats exposed to indomethacin (IndoM).
Control IndoM IndoM/AtoR
Catalase (U/g.tissue protein) 73.1  3.6 37.8  2.6a 62.6  3.2b
SOD (U/g.tissue protein) 58.1  2.7 30.4  1.6a 52.5  1.9b
MDA (nmol/g.tissue protein) 9.3  0.6 35.8  2.6a 16.1  1.6b
Nitrite/nitrate(nmol/g.tissue
protein)
26.9  2.1 8.8  0.8a 20.9  1.1b
Values are represented as means ± SEM of 8 observations. a Significant difference compared to control, b significant
difference compared to IndoM-treated group. Significant difference is reported when P < 0.05.
Effect of atorvastatin on gastric levels of PGE2 and TNF-α in indomethacin-treated rat
The IndoM-treated group showed induction of inflammatory signs as shown by the significant decrease in gastric tissue
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Administration of AtoR prior to IndoM challenge significantly increased PGE2, with decreasing TNF-α compared to the
group receiving IndoM alone (P < 0.05).
Figure 2: Effect of atorvastatin (AtoR) on tissue concentration of prostaglandin and tumor necrosis factor (TNF)-α in



























































The results are mean ± SEM for 8 animals/group. a
Significant difference compared to control. b Significant
difference compared from IndoM-treated group. c No
significant difference compared control untreated group.
Significant difference is reported when P < 0.05.
DISCUSSION:
The NSAIDs; IndoM, is used to ameliorate pain,
inflammation and hyperpyrexia, as well as to treat patent
ductus arteriosus in neonates.11 IndoM is also claimed to
have some anticancer activity.12 Despite its numerous
advantages, IndoM causes upper gastrointestinal
irritation amounting to ulcerations, which hinders its use.
Due to its known gastric ulcerogenic effect, IndoM has
been routinely applied to induce experimental animal
model of acute gastric ulcer. 2,3,7 In concurrence with
previous studies, here, IndoM caused an increase in ulcer
index and induced gastric oxidative stress, manifested by
the increase in tissue lipid peroxidation product; MDA,
with a decrease in gastric mucosal NO level, as well as
SOD and catalase antioxidant enzymatic activity.13-17 In
addition, in agreement with previous studies, IndoM
stimulated gastric mucosal inflammatory pathways,
evident by the decrease in PGE2.18,19 and the increment of
TNF-α level. 20,21
In a previous study, we showed that the anti-
hyperlipidemic drug; AtoR, possessed antioxidant and
anti-inflammatory effects against doxorubicin-induced
hepato-renal damage. 6 Here, we confirm our findings, as
AtoR, through antioxidant and anti-inflammatory
mechanisms, conferred gastro-protective effects against
IndoM-induced gastric ulcer. Interestingly, one previous
study contradicted our findings, and showed that AtoR
did not confer gastro-protection, but rather increased
ulcer index.22 The reason for such discrepancy is
probably due to the use of two- to four-folds higher doses
of AtoR in the latter study than the dose used in the
present study. Indeed, at higher doses, AtoR has been
reported to cause gastrointestinal bleeding and may even
induce colon carcinogenesis. 23 Antioxidant properties of
AtoR has been reported to be beneficial to multiple vital
organs, not only in conditions characterized by
hypercholesterolemia24 but also during normal lipid
profile cases, where AtoR's antioxidant features may
delay cardiac aging25, ameliorate neuropathic pain26 and
protect the kidney and liver against cytotoxic drug-
induced toxicity6. Another mechanism by which AtoR
performs its pharmacological effects is through induction
of NO synthesis by inducible form of nitric oxide
synthase enzyme (iNOS), as seen in the heart27 Here, we
show for the first time that NO level in the gastric
mucosa have been increased after AtoR pre-treatment,
succeeding to significantly reversing the decreased NO
level caused by IndoM. Some recent studies implicated
that AtoR also had anti-inflammatory properties6,28. Ator
was reported to ameliorate inflammatory pathways, as
that of TNF-α/NF-κB in the diabetic patients29 and high
fat diet-induced stress30. To date, the effect of AtoR on
gastric mucosal pro-inflammatory cytokine; TNF-α, has
not yet been elucidated. Here, we showed that AtoR
significantly decreased tissue level of TNF-α in gastric
mucosa.
Prostaglandins, especially PGE2, are essential for mediating gastro-protective effects, and their production is thought to be
downstream to induction of iNOS and the resultant increased NO formation.31 To our best knowledge, the current study is
the first to report that AtoR administration causes increase in gastric mucosal PGE2. Interestingly, AtorR seems to have
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differential effect on PGE2, as it was reported to decrease elevated PGE2 in patients with coronary artery disease patients32
and Sjögren's syndrome33, while it increased PGE2 in the myocardium34. The cross-talk between various antioxidant,
nitrosative and anti-inflammatory mechanistic pathways is not easy to explain35, indicating a multi-factorial reasons for
AtoR-induced gastro-protection.
CONCLUSION:
AtoR confers gastro-protection against IndoM-induced ulcerations through different mechanisms, including ameliorating
oxidative stress, increasing mucosal NO and PGE2, as well as decreasing the pro-inflammatory cytokine; TNF-α.
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